The launch of Sandoz's Tyruko biosimilar of Tysabri (natalizumab) comes two years after the product was approved by the FDA, ...

As the Jefferies Healthcare conference gets underway this week in London, pharmaphorum had the chance to connect with the CEO ...

Johnson & Johnson has added to the flurry of M&A deals in pharma with an agreement to buy US biotech Halda Therapeutics and ...

As ESMO 2025 came to a close last month, pharmaphorum had the pleasure of catching up with Dr Sandeep Reddy, Chief Medical ...

The announcement takes the total raised by Sofinnova Partners in the last year to €1.5 billion, and comes shortly after Anglo ...

BMS and J&J's Librexia AF study is also comparing milvexian to Eliquis to see if it can prevent stroke and other clotting ...

AbbVie has turned to award-winning, Oscar-nominated director Dominic Gill to help it highlight the lives of people living ...

A 2024 survey by the American Medical Association showed that physician usage of AI jumped 78% in a single year, which tells ...

The FDA is also requiring Sarepta to conduct an additional post-marketing observational study to further assess the risk of ...

In the Bax24 study reported at the AHA, aldosterone synthase inhibitor (ASI) baxdrostat achieved a 16.6 mm Hg reduction in 24 ...

In a statement, Avadel acknowledged that it had received the Lundbeck bid and that its board of directors had "determined in ...